BWP
AXSM icon

Baldwin Wealth Partners’s Axsome Therapeutics AXSM Stock Holding History

Baldwin Wealth Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Buy
44,070
+2,000
+5% +$434K 0.71% 34
2026
Q1 		$7.11M Sell
42,070
-6,500
-13% -$1.12M 0.52% 46
2025
Q4 		$8.87M Hold
48,570
– – 0.57% 44
2025
Q3 		$5.9M Hold
48,570
– – 0.38% 56
2025
Q2 		$5.07M Sell
48,570
-1,000
-2% -$106K 0.34% 58
2025
Q1 		$5.78M Hold
49,570
– – 0.41% 57
2024
Q4 		$4.19M Sell
49,570
-125
-0.3% -$11.5K 0.29% 61
2024
Q3 		$4.47M Hold
49,695
– – 0.3% 62
2024
Q2 		$4M Hold
49,695
– – 0.31% 64
2024
Q1 		$3.97M Buy
49,695
+700
+1% +$58.8K 0.3% 65
2023
Q4 		$3.9M Buy
48,995
+1,000
+2% +$66.9K 0.31% 64
2023
Q3 		$3.35M Hold
47,995
– – 0.29% 69
2023
Q2 		$3.45M Buy
47,995
+500
+1% +$36.9K 0.28% 74
2023
Q1 		$2.93M Hold
47,495
– – 0.26% 79
2022
Q4 		$3.66M Sell
47,495
-5,350
-10% -$320K 0.33% 75
2022
Q3 		$2.36M Hold
52,845
– – 0.33% 48
2022
Q2 		$2.02M Sell
52,845
-2,000
-4% -$63.3K 0.26% 53
2022
Q1 		$2.27M Buy
54,845
+13,000
+31% +$403K 0.24% 57
2021
Q4 		$1.58M Hold
41,845
– – 0.16% 65
2021
Q3 		$1.38M Buy
41,845
+17,000
+68% +$663K 0.15% 64
2021
Q2 		$1.68M Hold
24,845
– – 0.18% 62
2021
Q1 		$1.41M Sell
24,845
-500
-2% -$35.2K 0.17% 66
2020
Q4 		$2.06M Buy
25,345
+500
+2% +$37.4K 0.26% 55
2020
Q3 		$1.77M Hold
24,845
– – 0.24% 60
2020
Q2 		$2.04M Hold
24,845
– – 0.3% 59
2020
Q1 		$1.46M Sell
24,845
-10,396
-29% -$847K 0.26% 62
2019
Q4 		$3.64M Buy
35,241
+5,500
+18% +$222K 0.51% 54
2019
Q3 		$602K Buy
29,741
+500
+2% +$12.8K 0.09% 95
2019
Q2 		$753K Hold
29,241
– – 0.11% 96
2019
Q1 		$416K Hold
29,241
– – 0.06% 141
2018
Q4 		$82K Sell
29,241
-1,310
-4% -$4.31K 0.01% 246
2018
Q3 		$105K Buy
30,551
+5,000
+20% +$14.8K 0.01% 247
2018
Q2 		$82K Buy
25,551
+6,000
+31% +$18.6K 0.01% 271
2018
Q1 		$48K Hold
19,551
– – 0.01% 300
2017
Q4 		$109K Hold
19,551
– – 0.02% 239
2017
Q3 		$109K Sell
19,551
-100
-0.5% -$537 0.02% 229
2017
Q2 		$108K Hold
19,651
– – 0.02% 231
2017
Q1 		$77K Hold
19,651
– – 0.01% 260
2016
Q4 		$133K Buy
19,651
+4,500
+30% +$31.6K 0.02% 201
2016
Q3 		$119K Buy
+15,151
New +$115K 0.02% 211

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
CA
Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return

Baldwin Wealth Partners's AXSM Position: Q2 2026 in Review

Baldwin Wealth Partners increased its Axsome Therapeutics (AXSM) stake by 4.8% in Q2 2026, buying an estimated $434K and bringing the position to 44,070 shares worth $10.8M. The position accounts for 0.71% of the portfolio, ranked #34.

Baldwin Wealth Partners first reported a position in AXSM in Q3 2016 and has held it in 40 quarters since. 38 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Baldwin Wealth Partners held 44,070 shares of Axsome Therapeutics worth $10.8M as of Q2 2026.
  • Baldwin Wealth Partners bought 2,000 Axsome Therapeutics shares in Q2 2026, an estimated $434K.
  • Axsome Therapeutics made up 0.71% of Baldwin Wealth Partners's portfolio in Q2 2026, its #34 holding.
  • Baldwin Wealth Partners first reported a position in Axsome Therapeutics in Q3 2016 and has held it in 40 quarters since.
  • 38 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Baldwin Wealth Partners's 13F filing for Q2 2026, filed 14 Jul 2026.